Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough

Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced the presentation of results from a Phase 2 study
evaluating the safety, efficacy and therapeutic dose range of MK-7264
(formerly AF-219) for the treatment of chronic cough. The highest dose
evaluated, 50 mg, reduced Awake Cough Frequency (coughs/hour), the
primary endpoint, by 37 percent from baseline relative to placebo
(p=0.003). The 50 mg dose also demonstrated a reduction in
patient-reported cough severity.Language:
EnglishContact: MerckMedia:Pamela Eisele , 267-305-3558orKate Prout, 267-980-7601orInvestors:Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more

Source: Merck.com - Research and Development News - May 22, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK chronic cough MSD NYSE:MRK Source Type: news